Sunday, 16 August 2026European Markets
ExploreSearch
ViaNews EU
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 6, 2026

Eli Lilly reports broad benefits for experimental obesity drug retatrutide

View original at seekingalpha.com
Eli Lilly reports broad benefits for experimental obesity drug retatrutide [Worried mature man measuring his waist in a living room] Ljupco/iStock via Getty Images Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Retatrutide improved triglycerides, non-HDL cholesterol, blood pressure, and waist circumference across both studies

    60% confidence

  • Retatrutide reduced breathing interruptions in obstructive sleep apnea by up to 36.1 events per hour, representing roughly a 61% improvement

    60% confidence

  • Highest-dose T2D patients lost average 36.6 pounds (16.8% body weight) and weight loss had not yet leveled off by study end

    60% confidence

  • In TRIUMPH-1, adults with obesity receiving the highest dose of retatrutide lost an average of 70.3 pounds (28.3% body weight) after 80 weeks

    60% confidence

  • About one-third of highest-dose participants reached a BMI below 25, generally considered a healthy weight range

    60% confidence

  • GLP-1 drug market sales forecast raised to $150 billion

    60% confidence

  • In TRANSCEND-T2D-1, retatrutide reduced A1C levels by up to 2 percentage points over 40 weeks in type 2 diabetes patients starting at an average A1C of 7.9%

    60% confidence

  • Up to 90% of type 2 diabetes patients receiving retatrutide achieved A1C below 7%; nearly half reached A1C below 5.7% (normal range)

    60% confidence

  • Retatrutide reduced knee osteoarthritis pain scores by as much as 73%

    60% confidence

  • Among more severely obese participants treated for two years, average weight loss reached 85 pounds (38.56 kg)

    60% confidence

  • More than 65% of highest-dose TRIUMPH-1 participants reduced BMI below 30, no longer meeting the medical definition of obesity

    60% confidence

  • Discontinuation rates due to side effects ranged from approximately 2% to 11% depending on study and dose level

    60% confidence